

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SIDNEY <i>et al.</i> Appl. No.: 10/530,061 Filed: April 4, 2005 For: HLA Binding Peptides and Their Uses	Confirmation No.: 7448 Art Unit: 1643 Examiner: BRISTOL, Lynn Anne Atty. Docket: 2473.0330002/EKS/PAC
---	--

Information Disclosure Statement

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed after the mailing of a final Office Action and with the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. No statement or fee is required.


Copies of documents FP1-FP10 and NPL1-NPL13 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached IDS Forms are submitted.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Paul A. Calvo
Attorney for Applicants
Registration No. 57,913

Date: April 12, 2010

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1038512_1.DOC